Krystal Biotech (NASDAQ:KRYS) Shares Gap Down – What’s Next?

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) gapped down before the market opened on Wednesday . The stock had previously closed at $156.69, but opened at $149.25. Krystal Biotech shares last traded at $164.70, with a volume of 78,905 shares traded.

Analyst Ratings Changes

KRYS has been the subject of a number of research reports. Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Finally, Chardan Capital restated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Price Performance

The company has a market cap of $4.93 billion, a P/E ratio of 97.01 and a beta of 0.84. The stock has a 50-day moving average of $157.40 and a 200 day moving average of $175.17.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Sell-side analysts predict that Krystal Biotech, Inc. will post 3.22 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of the business. US Bancorp DE boosted its stake in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock worth $407,000 after acquiring an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after purchasing an additional 121 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in shares of Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after purchasing an additional 123 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).